GUACETISAL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H14O5
Molecular Weight	286.2794
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=CC=C1OC(=O)C2=C(OC(C)=O)C=CC=C2

InChI

InChIKey=HSJFYRYGGKLQBT-UHFFFAOYSA-N

InChI=1S/C16H14O5/c1-11(17)20-13-8-4-3-7-12(13)16(18)21-15-10-6-5-9-14(15)19-2/h3-10H,1-2H3

HIDE SMILES / InChI

Molecular Formula	C16H14O5
Molecular Weight	286.2794
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7017495 | https://www.ncbi.nlm.nih.gov/pubmed/7017483 | https://www.ncbi.nlm.nih.gov/pubmed/7017492 | https://www.ncbi.nlm.nih.gov/pubmed/7017493

Guacetisal (Broncaspin) is a bronchomucotropic synthesized by the Bayer Italia S.p.A. Research Laboratories. It is obtained from the esterification of acetylsalicylic acid with guaiacol. Guacetisal was used for the treatment of chronic bronchitis and other inflammatory diseases of the respiratory tract. Guacetisal, used rectally, proved to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1941545 \| https://www.ncbi.nlm.nih.gov/pubmed/9187256	Inhibitor 8504

PubMed

Title	Date	PubMed
[Broncaspin in respiratory diseases in pediatrics. Clinical contribution].	1981-02-28	7017493
[Controlled clinical study of the treatment of chronic bronchitis with guacetisal].	1981-02-28	7017483
[Clinical study of a preparation with bronchomucotropic activity: guacetisal].	1981-02-28	7017495

Patents

Sample Use Guides

In Vivo Use Guide

Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect.

Route of Administration: Rectal

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:58:43 GMT 2025` Edited by `admin` on `Mon Mar 31 17:58:43 GMT 2025`
Record UNII	T6EKB9V2O2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GUACETISAL

Official Name

English

ASPIRIN GUAIACOL ESTER

Preferred Name

English

guacetisal [INN]

Common Name

English

Guacetisal [WHO-DD]

Common Name

English

GUACETISAL [MART.]

Common Name

English

PRONTOMUCIL

Brand Name

English

O-METHOXYPHENYL SALICYLATE ACETATE

Common Name

English

ASPIRIN GUAIACOL ESTER [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N02BA14